- Previous Close
37.05 - Open
37.30 - Bid 37.05 x --
- Ask 37.15 x --
- Day's Range
36.75 - 37.65 - 52 Week Range
25.14 - 47.20 - Volume
185,832 - Avg. Volume
466,855 - Market Cap (intraday)
19.567B - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.01 - Earnings Date Feb 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
48.01
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
vimian.com1,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VIMIAN.ST
View MorePerformance Overview: VIMIAN.ST
Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIMIAN.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIMIAN.ST
View MoreValuation Measures
Market Cap
19.41B
Enterprise Value
21.85B
Trailing P/E
198.70
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.49
Price/Book (mrq)
2.53
Enterprise Value/Revenue
5.39
Enterprise Value/EBITDA
27.09
Financial Highlights
Profitability and Income Statement
Profit Margin
0.07%
Return on Assets (ttm)
2.51%
Return on Equity (ttm)
0.16%
Revenue (ttm)
352.39M
Net Income Avi to Common (ttm)
256k
Diluted EPS (ttm)
-0.01
Balance Sheet and Cash Flow
Total Cash (mrq)
39.17M
Total Debt/Equity (mrq)
37.62%
Levered Free Cash Flow (ttm)
-49.33M